The Market for Biologic Drugs

Are biosimilars priced similarly to generics? According to Ana Nicholls, healthcare analyst at The Economist Intelligence Unit, the answer is no: “Given the lower levels of competition in the biosimilars market, the copies tend to be priced at just 20-30% below the original drugs, compared with around 90% below for traditional generics.” (Jason Shafrin)



via John Goodman's Health Policy Blog http://ift.tt/1fLtmGm